The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq^®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival (DFS) with the addition of atezolizumab, an anti-PD-L1 monoclonal antibody, to standard adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin). The data are being presented today at 1:05 pm CDT/2:05 pm ET during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA1) by Alliance Study Chair Frank Sinicrope, MD.

Dana-Farber Cancer Institute presents potentially practice changing results from the phase 3 ASCENT-04/KEYNOTE-D19 clinical trial at American Society of Clinical Oncology (ASCO) annual meeting

May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.